Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative depression in elderly gastrointestinal tumor patients undergoing laparoscopic surgery
ChiCTR2400091020Phase 4Completed
- Sponsor
- Changzhi People's Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) and gastrointestinal cancer (2 arms), sponsored by Changzhi People's Hospital. Primary endpoints: Postoperative depressive symptoms and Sleep monitoring. Started Oct 2024; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)gastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2400091020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091020.